Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
週五報告，神經分泌生物科學的CRENESSITY獲得FDA批准，徹底改變經典先天性腎上腺增生的治療。
- CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach
- FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAHCRENESSITY is expected to be commercially available in approximately one week
Rare Pediatric Disease Priority Review Voucher granted in connection with approval
- FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAHCRENESSITY is expected to be commercially available in approximately one week
- CRENESSITY是70年來第一種新治療方案，爲經典先天性腎上腺皮質增生（CAH）社區提供了一個改變遊戲規則的治療方法
- FDA的批准得到了針對經典CAH的兒童和成人患者中最大規模臨床試驗項目的數據支持，CRENESSITY預計將在大約一週內商業上市
在批准過程中授予的稀有兒科疾病優先審查憑證
- FDA的批准得到了針對經典CAH的兒童和成人患者中最大規模臨床試驗項目的數據支持，CRENESSITY預計將在大約一週內商業上市
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。